Market Place
Sourcing Support
MaaT Pharma Presents Updates from Early Access Program in aGvHD
07 Nov 2024 //
BUSINESSWIRE
MaaT Pharma Q3 2024 Results & Management Changes Announced
05 Nov 2024 //
BUSINESSWIRE
MaaT Pharma Completes Recruitment Of ARES Phase 3 Trial For
15 Oct 2024 //
BUSINESSWIRE
MaaT Pharma Publishes Half Year 2024 Results And Update
19 Sep 2024 //
BUSINESSWIRE
MaaT Pharma to Present and Join Investor and Medical Conferences in September
04 Sep 2024 //
BUSINESSWIRE
MaaT Pharma Announces Positive DSMB Review For MaaT033 Phase 2 Trial
02 Jul 2024 //
BUSINESSWIRE
MaaT Pharma Coverage Initiated with Buy Rating, EUR 16 Target Price by Stifel
25 Jun 2024 //
BUSINESSWIRE
MaaT Pharma appoints Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer.
24 Jun 2024 //
BUSINESSWIRE
MaaT Pharma Business Update And 2024 Milestones
07 May 2024 //
BUSINESSWIRE
Mustang Bio to lay off workers; MaaT`s new data for microbiome therapy
15 Apr 2024 //
ENDPTS
MaaT: Positive 18-Month aGvHD Survival For MaaT013
15 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034
08 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont
05 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
28 Mar 2024 //
BUSINESSWIRE
MaaT Strengthens Executive Team Appointing Chriqui as Chief Business Officer
21 Mar 2024 //
BUSINESSWIRE
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming
19 Mar 2024 //
BUSINESSWIRE
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013
12 Mar 2024 //
BUSINESSWIRE
MaaT indicates completion of Recruitment for Phase 2a Evaluating MaaT013
05 Mar 2024 //
BUSINESSWIRE
MaaT Pharma Announces Positive Review from Phase 1 Trial Evaluating MaaT033
29 Feb 2024 //
BUSINESSWIRE
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033
12 Dec 2023 //
BUSINESSWIRE
MaaT Pharma Presents Positive Results with Lead Product MaaT013
11 Dec 2023 //
BUSINESSWIRE
MaaT Pharma Awarded Government Funding for MaaT033
30 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Provides Third Quarter 2023 Reports Financial Results
09 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Announces First Patient Dosed in Phase 2b Trial Evaluating MaaT033
06 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033
02 Nov 2023 //
BUSINESSWIRE
MaaT Pharma to Present Preclinical Data at SITC on MaaT034
31 Oct 2023 //
BUSINESSWIRE
MaaT Pharma Announces Positive Outcome in Phase 3 with MaaT013
26 Oct 2023 //
BUSINESSWIRE
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting
27 Sep 2023 //
BUSINESSWIRE
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
26 Sep 2023 //
BUSINESSWIRE
MaaT and Skyepharma Complete Construction of Largest Manufacturing Facility
12 Sep 2023 //
BUSINESSWIRE
MaaT Pharma Announces EMA Granted MaaT033 ODD aiming to improve overall survival
06 Sep 2023 //
BUSINESSWIRE
MaaT Pharma Provides Q2 2023 Business Update and Reports Financial Results
27 Jul 2023 //
BUSINESSWIRE
MaaT Announces Publication of Results in eClinicalMedicine Journal Highlighting Benefit of MaaT013
26 Jul 2023 //
BUSINESSWIRE
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
20 Jul 2023 //
BUSINESSWIRE
FDA lifts nearly two-year hold on MaaT`s microbiome therapy, opens door to PIII
25 Apr 2023 //
ENDPTS
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Inda for MaaT013
24 Apr 2023 //
BUSINESSWIRE
MaaT Pharma to Present Data for MaaT013 and MaaT033 at EBMT Annual Meeting
11 Apr 2023 //
BUSINESSWIRE
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
30 Mar 2023 //
BUSINESSWIRE
MaaT Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033
27 Mar 2023 //
BUSINESSWIRE
MaaT Pharma Receives U.S. FDA Response for Investigational NDA for MaaT013
03 Feb 2023 //
BUSINESSWIRE
After 18-month hold, MaaT sees end to impasse with FDA
03 Feb 2023 //
FIERCE BIOTECH
MaaT Provides Corporate Update and Highlights Key Expected Milestones in 2023
24 Jan 2023 //
BUSINESSWIRE
MaaT Pharma Presents Promising Results from Phase 1b Trial with MaaT033
11 Dec 2022 //
BUSINESSWIRE
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data
10 Dec 2022 //
BUSINESSWIRE
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
29 Nov 2022 //
BUSINESSWIRE
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
08 Nov 2022 //
BUSINESSWIRE
MaaT Announces Participation in Scientific and Investor Conferences in November
07 Nov 2022 //
BUSINESSWIRE
MaaT Pharma AnnouncesPresentations at the 64th ASH Annual Meeting
03 Nov 2022 //
BUSINESSWIRE
MaaT Pharma Appoints Nathalie Corvaïa as CSO and Strengthens its R&Dgy
04 Oct 2022 //
BUSINESSWIRE
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer
04 Oct 2022 //
BUSINESSWIRE
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview
29 Sep 2022 //
BUSINESSWIRE
MaaT Announces Participation in Three Upcoming Investor Conferences in September
08 Sep 2022 //
BUSINESSWIRE
1 year into clinical hold, FDA has questions about `pooled` microbiome therapy
11 Aug 2022 //
ENDPOINTS NEWS
FDA declines to free MaaT`s microbiome drug from clinical hold after a year
11 Aug 2022 //
FIERCE BIOTECH
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
28 Jul 2022 //
BUSINESSWIRE
MaaT Pharma reports positive data from Phase Ib blood cancer trial
03 Jun 2022 //
CLINICALTRIALSARENA
MaaT Pharma Confirms +ve Results from PIb CIMON Study of MaaT033
02 Jun 2022 //
BUSINESSWIRE
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
24 May 2022 //
BUSINESSWIRE
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
05 May 2022 //
BUSINESSWIRE
INRAE and MaaT Pharma to develop Drug-Candidate MaaT013 into PIII Trial
20 Apr 2022 //
BUSINESSWIRE
